Kodiak Sciences Inc. (KOD): R&D Expense
$182.37M
Year ended 2025-12-31
$200.60M
Trailing 12 months to 2026-06-30
-12.0%
3-year compound annual growth
+11.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $182.37M | +44.6% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $126.09M | -38.9% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $206.30M | -22.9% | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | $267.59M | +23.1% | 2025-03-27, From 2022-01-01 |
| 2021-12-31 | $217.34M | +102.4% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $107.39M | +186.3% | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | $37.51M | +99.6% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $18.79M | -14.7% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $22.02M | +56.7% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $14.05M | n/a | 2019-03-27, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $182.37M | +44.6% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $86.40M | +30.9% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $160.64M | +3.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
| Prokidney Corp. (PROK) | 2025-12-31 | $114.12M | -10.6% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $221.18M | +16.8% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $108.45M | +29.9% |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗